The antiviral is already authorized in the U.K. The FDA isn’t bound by the panel’s recommendation and is expected to make its own decision before year’s end. Most experts also said the drug shouldn't be used in vaccinated people, who weren't part of Merck’s research and haven't been shown to benefit. The vote specifically backed the drug for adults with mild-to-moderate COVID-19 who face the greatest risks, including older people and those with conditions like obesity and asthma. Most experts backing the treatment stressed that it should not be used by anyone who is pregnant and called on FDA to recommend extra precautions before the drug is prescribed, such as pregnancy tests for women of child-bearing age. The recommendation came after hours of debate about the drug’s modest benefits and potential safety issues. ‘The Virus Is a Ruthless Opportunist': Global Vaccine Inequality Linked to Omicron
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |